SITE004-0128

SITE004 (DEU) › SITE004-0128

SITE004-0128

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2026-02-05

completed

AEs

6

Serious

1

Dropout signal

–

Adverse events

6

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-01-07 (study day 152); relationship: not assessed

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-10-19 (study day 72); relationship: not assessed

moderate assessed

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-18 (study day 71); relationship: RELATED

severe assessed

Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-01 (study day 54); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-09-08 (study day 31); relationship: not assessed

moderate assessed

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-08-25 (study day 17); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.